Cocrystals « New Drug Approvals

Cocrystals « New Drug Approvals:



'via Blog this'

THANKS AND REGARD'S
DR ANTHONY MELVIN CRASTO Ph.D
amcrasto@gmail.com

MOBILE-+91 9323115463

GLENMARK SCIENTIST ,  INDIA
web link

ABOUTME

BRAND ANTHONYCRASTO

COLLECTION OF SITE LINKS

http://amcrasto.bravesites.com/

http://anthonycrasto.jimdo.com/

Congratulations! Your presentation titled "Anthony Crasto Glenmark scientist, helping millions with websites" has just crossed MILLION views.

アンソニー     安东尼   Энтони    안토니     أنتوني

join my process development group on google

organic-process-development group

you can post articles and will be administered by me on the google group which is very popular across the world

https://sites.google.com/site/amcrasto/

SKILLPAGES

MIXXT

APNACIRCLE

LinkedIn group

SYNTHETIC ORGANIC CHEMISTRY

 
blogs are 

• Green Chemistry International,  
• Eurekamoments in Organic Chemistry ,   
• WIX CHEMISTRY BLOG , 
• Drug regulatory affairs international 
• ORGANIC CHEMISTRY SELECT
• ORGANIC SPECTROSCOPY INTERNATIONAL 
• ORGANIC SYNTHESIS INTERNATIONAL 
• ORGANIC CHEMISTRY INTERNATIONAL

MY BLOG ON MED CHEM
New Drug Approvals
ALL ABOUT DRUGS
WORLD DRUG TRACKER
MEDICINAL CHEM INTERNATIONAL
DRUG SYN INTERNATIONAL
SCALEUP OF DRUGS
ALL FOR DRUGS ON WEB
http://scholar.google.co.uk/citations?user=bxm3kYkAAAAJ

MY CHINA AND JAPAN BLOGS

http://amcrasto.blog.fc2.com/

http://blog.sina.com.cn/u/5030268874

http://ameblo.jp/medchem-amcrasto/

VIETNAM
http://me.zing.vn/u/amcrasto
ICELAND
http://amcrasto.bland.is/
RUSSIA
http://www.100zakladok.ru/amcrasto/
http://bobrdobr.ru/people/amcrasto/

 

Investigators in the Fight Against Scurvy

Achievements from the first attempts to cure vitamin C deficiency to the isolation, structure determination and synthesis of vitamin C
Read more

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech: Pharma Trends: Predictions for 2014-2015by Jon Wet...

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech: Pharma Trends: Predictions for 2014-2015by Jon Wet...: Pharma Trends: Predictions  for 2014-2015 by   Jon Wetzel To look forward we need to first look back.  From 2008-2012 we saw b...

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech: PHARMA DEALS DURING FEBRUARY 2014As is customary ...

MANAGEMENT SOLUTIONS GROUP LatAm - Gestión de Organizaciones de Salud, Farma & Biotech:
PHARMA DEALS DURING FEBRUARY 2014As is customary ...: PHARMA DEALS DURING FEBRUARY 2014 As is customary this month's report focuses mainly on deals with disclosed fina...

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell | lyranara.me

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell | lyranara.me:



'via Blog this'

Study identifies enzymes that help fix cancer-causing DNA defects | lyranara.me

Study identifies enzymes that help fix cancer-causing DNA defects | lyranara.me:



'via Blog this'

Emerging classes of armed antibody therapeutics against cancer

http://pubs.rsc.org/en/Content/ArticleLanding/2014/MD/C3MD00360D?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+rss%2FMD+%28RSC+-+Med.+Chem.+Commun.+latest+articles%29#!divAbstract

Med. Chem. Commun., 2014, 5,408-431
DOI: 10.1039/C3MD00360D, Review Article

Christian Hess, Dario Venetz, Dario Neri
There is a trend in oncology towards the development of 'armed' antibody products. In this article,

some of the most advanced preclinical and clinical activities in the field of armed
antibodies are reviewed.

Monoclonal antibodies represent the largest and fastest growing type of biopharmaceuticals. 
Their commercial and clinical success has fueled research activities aiming to improve safety 
and efficacy. In oncology, there is a trend towards the development of ‘armed’ antibody products,
 in which the immunoglobulin moiety serves for the selective in vivo pharmacodelivery 
of bioactive payloads such as cytotoxic drugs, bispecific antibodies, 
radionuclides or cytokines to sites of disease, thereby sparing healthy tissues. 
In this article, we review some of the most advanced preclinical and clinical 
activities in the field of armed antibodies and present a personal perspective 
on the opportunities and challenges associated with the use of this type of anti-cancer therapeutics.